Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 12, 2016. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It solely reports on a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of ordinary shares under the Company's ShareReward Plan.
- Transaction Price: £16.7127 per share.
- Volume: 14 ordinary shares total (comprising 7 partnership shares and 7 matching shares).
- Transaction Date: July 11, 2016.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not contain comparative financial data or material changes to the company's financial position versus prior periods. It reports a single, routine transaction under an employee share plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a regulatory disclosure of a transaction by a Person Discharging Managerial Responsibilities (PDMR).
Investor Verification Points
- Verify the identity of the PDMR involved: Mr. P C Thomson, SVP, Communications & Government Affairs.
- Confirm the transaction was executed under the ShareReward Plan as stated.
- Note that this filing does not reflect broader company performance; refer to Form 20-F for financial results.